| abstract |
An ophthalmic aqueous suspension preparation to serve as a cure for corneal herpes infection contains 9-[(2-hydroxyethoxy)methyl]guanine as an active ingredient and exhibits an improved stability. Specifically, the ophthalmic aqueous suspension preparation contains 0.2 to 5% by weight of 9-[(2-hydroxyethoxy)methyl]guanine or a pharmaceutically acceptable salt thereof, 0.05 to 1% by weight of a partially saponified product of polyvinyl acetate, and 0.01 to 1% by weight of a nonionic surfactant and has a pH of 6 to 8. Preferably, the fine crystals have a short axis of 50 μm or less and a long axis of 70 μm or less in length and have a ratio of the long axis to the short axis of 10:1 or less. |